AI responses may include mistakes. For financial advice, consult a professional. Learn more
: Official 2026 guidance forecasts revenue between $59.5 billion and $62.5 billion , a slight decline from 2025 levels. This "soft" outlook has led many major brokerages, such as Bank of America and Bernstein , to maintain "Neutral" or "Hold" ratings.
: The success of Pfizer's $43 billion Seagen acquisition and its internal obesity assets is critical. Any setbacks in late-stage trials or slower-than-expected integration of new assets could further delay the "growth inflection" point, currently estimated for 2028 or 2029 . Summary of Analyst Outlook Metric / Sentiment Consensus Rating Moderate Buy / Hold Average Price Target ~$28.48 to $29.42 Dividend Yield 6.37% – 6.51% 2026 EPS Guidance $2.80 – $3.00
: To offset the loss of exclusivity (LOE) on blockbusters like Eliquis and Ibrance, Pfizer is aggressively reinvesting in oncology and obesity. Key 2026 catalysts include the start of 20 pivotal clinical trials , notably in the high-growth GLP-1 (obesity) market and next-generation cancer therapies. Key Risks and Headwinds
: Pfizer remains a premier income stock, offering a 6.42% dividend yield . Management has reaffirmed its commitment to the dividend, declaring a $0.43 per share payout for the second quarter of 2026. While the payout ratio is elevated, management's cost-realignment program—targeting $7.2 billion in cumulative savings by 2027 —is intended to protect these cash returns.
Potential buyers must weigh the value proposition against structural challenges that may limit near-term price appreciation:
Buy Pfizer Stock | 2027 |
AI responses may include mistakes. For financial advice, consult a professional. Learn more
: Official 2026 guidance forecasts revenue between $59.5 billion and $62.5 billion , a slight decline from 2025 levels. This "soft" outlook has led many major brokerages, such as Bank of America and Bernstein , to maintain "Neutral" or "Hold" ratings.
: The success of Pfizer's $43 billion Seagen acquisition and its internal obesity assets is critical. Any setbacks in late-stage trials or slower-than-expected integration of new assets could further delay the "growth inflection" point, currently estimated for 2028 or 2029 . Summary of Analyst Outlook Metric / Sentiment Consensus Rating Moderate Buy / Hold Average Price Target ~$28.48 to $29.42 Dividend Yield 6.37% – 6.51% 2026 EPS Guidance $2.80 – $3.00
: To offset the loss of exclusivity (LOE) on blockbusters like Eliquis and Ibrance, Pfizer is aggressively reinvesting in oncology and obesity. Key 2026 catalysts include the start of 20 pivotal clinical trials , notably in the high-growth GLP-1 (obesity) market and next-generation cancer therapies. Key Risks and Headwinds
: Pfizer remains a premier income stock, offering a 6.42% dividend yield . Management has reaffirmed its commitment to the dividend, declaring a $0.43 per share payout for the second quarter of 2026. While the payout ratio is elevated, management's cost-realignment program—targeting $7.2 billion in cumulative savings by 2027 —is intended to protect these cash returns.
Potential buyers must weigh the value proposition against structural challenges that may limit near-term price appreciation:
Non viene rilasciata alcuna garanzia né dichiarazione in relazione all'accuratezza di tali informazioni e si declina qualsiasi responsabilità per errori tipografici o d'altro tipo, per omissioni nel contenuto o per un'errata associazione di accessori e di consumabili al prodotto principale.
